
Inventiva
IVA | PA
Overview
Corporate Details
- ISIN(s):
- FR0013233012 (+2 more)
- LEI:
- 969500I9Y690B3FZW590
- Country:
- France
- Address:
- 50 RUE DE DIJON, 21121 DAIX
- Website:
- https://inventivapharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Inventiva is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapies for diseases with significant unmet medical needs. The company's research and development primarily target fibrosis, lysosomal storage disorders, and oncology. Its lead drug candidate, lanifibranor, is in a pivotal Phase III trial for the treatment of Non-Alcoholic Steatohepatitis (NASH) and has received Breakthrough Therapy Designation from the FDA. Another clinical candidate, odiparcil, targets Mucopolysaccharidosis (MPS). Inventiva's pipeline is supported by a proprietary discovery platform, which includes an extensive library of approximately 240,000 molecules, a wholly-owned research facility, and expertise in compounds that modulate nuclear receptors and transcription factors.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Inventiva.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2025-08-19 15:35 |
Major Shareholding Notification
Franchissement de seuil
|
French | 116.8 KB | |
2025-08-19 15:32 |
Major Shareholding Notification
Franchissement de seuil
|
French | 116.7 KB | |
2025-08-19 15:19 |
Major Shareholding Notification
Franchissement de seuil
|
French | 116.1 KB | |
2025-08-12 15:57 |
Major Shareholding Notification
Franchissement de seuil
|
French | 113.9 KB | |
2025-08-12 15:52 |
Major Shareholding Notification
Franchissements de seuil
|
French | 121.6 KB | |
2025-08-11 15:14 |
Major Shareholding Notification
Franchissement de seuil
|
French | 121.9 KB | |
2025-06-17 17:02 |
Major Shareholding Notification
Franchissement de seuils
|
French | 113.4 KB | |
2025-06-10 22:00 |
Board/Management Information
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Di…
|
English | 243.0 KB | |
2025-05-27 22:00 |
Regulatory News Service
Inventiva Participera à la « Jefferies Global Healthcare Conference » et à la «…
|
French | 217.7 KB | |
2025-05-27 22:00 |
Regulatory News Service
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference…
|
English | 160.0 KB | |
2025-05-23 08:30 |
Earnings Release
Inventiva reports 2025 First Quarter Financial Information¹
|
English | 299.4 KB | |
2025-05-23 08:30 |
Earnings Release
Inventiva publie ses informations financières¹ du 1er trimestre 2025
|
French | 335.4 KB | |
2025-05-23 08:00 |
Declaration of Voting Results & Voting Rights Announcements
Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2…
|
English | 348.3 KB | |
2025-05-23 08:00 |
Post-Annual General Meeting Information
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunies le 2…
|
French | 347.8 KB | |
2025-05-22 14:00 |
Transaction in Own Shares
Descriptif du Programme de Rachat d’Actions Pouvant Être Mis en Œuvre dans le C…
|
French | 275.8 KB |
Automate Your Workflow. Get a real-time feed of all Inventiva filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Inventiva via our API.
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
2024-04-05 | N/A | Other | Buy | 10,000 | N/A |
2023-12-08 | N/A | Other | Buy | 15,000 | N/A |